EUVIMEDEUVIMED entdecken
Crossref

Can 18F-FDG PET/CT SUVmax values predict breast and axillary pathological complete response before neoadjuvant chemotherapy in breast cancer?

Ali Ihsan Saglam, Bulent Koca, Murat Yildirim, Ugur Ozsoy

Cirugía y Cirujanos (English Edition) · 30.10.2026 · 94 (4)

DOI: 10.24875/cirue.m24000969 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cirugía y Cirujanos (English Edition), online erschienen am 30.10.2026. Verfasst von Ali Ihsan Saglam und 3 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction Breast cancer is the most common type of cancer in women. Neoadjuvant chemotherapy (NAC) has become the initial treatment for locally advanced breast cancer.1 Its use has expanded after the recommendation for using NAC to T1c-N0 patients with human epidermal growth factor receptor 2 (HER2) positive and triple negative in the 2023 NCCN guideline. […]

Zitieren

APA

Saglam, A. I., Koca, B., Yildirim, M., & Ozsoy, U. (2026). Can 18F-FDG PET/CT SUVmax values predict breast and axillary pathological complete response before neoadjuvant chemotherapy in breast cancer?. Cirugía y Cirujanos (English Edition), 94(4). https://doi.org/10.24875/cirue.m24000969

Vancouver

Saglam AI, Koca B, Yildirim M, Ozsoy U. Can 18F-FDG PET/CT SUVmax values predict breast and axillary pathological complete response before neoadjuvant chemotherapy in breast cancer?. Cirugía y Cirujanos (English Edition). 2026;94(4). doi:10.24875/cirue.m24000969

BibTeX
@article{Saglam2026,
  author = {Saglam, Ali Ihsan and Koca, Bulent and Yildirim, Murat and Ozsoy, Ugur},
  title = {Can 18F-FDG PET/CT SUVmax values predict breast and axillary pathological complete response before neoadjuvant chemotherapy in breast cancer?},
  journal = {Cirugía y Cirujanos (English Edition)},
  year = {2026},
  volume = {94},
  number = {4},
  doi = {10.24875/cirue.m24000969}
}
Kostenlos starten →